SLC5A2 and chronic kidney disease: Treatment of other comorbidities in HF patients, including DM, is considered important, and choice of DM therapy should be influenced by the presence of HF.17 20 Specifically, SGLT2-inhibitors are effective both in the treatment of DM and HF (regardless of LVEF or DM status), as well as chronic kidney disease,14 17 20 33 which are all conditions with high overlap.